Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study
Sorafenib combined with tislelizumab and TACE showed promising antitumor activities with a manageable safety profile in patients with advanced-stage HCC. These preliminary findings warrant further evaluation in Phase III randomized trials.
Authors
- Jingjun Huang (ORCID: https://orcid.org/0000-0003-2582-6629)
- Licong Liang
- Mingyue Cai (ORCID: https://orcid.org/0000-0003-1155-9638)
- Wenbo Shi
- Xiaoyang Hong
- Kangshun Zhu (ORCID: https://orcid.org/0000-0001-5142-010X)
- Wensou Huang (ORCID: https://orcid.org/0000-0002-7412-6285)
- Yongjian Guo (ORCID: https://orcid.org/0009-0007-8775-1614)
- Jingwen Zhou (ORCID: https://orcid.org/0000-0003-1786-2574)
- Ye Chen (ORCID: https://orcid.org/0000-0003-3671-2504)
- Liteng Lin (ORCID: https://orcid.org/0000-0001-6617-1556)
- Zhimei Zhou
- Juan Liu
- Z. Lin
Institutions
- Shantou University (CN)
- Second Affiliated Hospital of Guangzhou Medical University (CN)
- Yue Bei People's Hospital (CN)
- Precision for Medicine (United States) (US)
- Shanghai Sixth People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/itt.s543741
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- American Society of Clinical Oncology
- Guangzhou Medical University
- BeiGene
- National Natural Science Foundation of China
- Southern Medical University